Literature DB >> 16914601

Adiponutrin gene is regulated by insulin and glucose in human adipose tissue.

Marthe Moldes1, Geneviève Beauregard, May Faraj, Noël Peretti, Pierre-Henri Ducluzeau, Martine Laville, Rémi Rabasa-Lhoret, Hubert Vidal, Karine Clément.   

Abstract

OBJECTIVE: Adiponutrin is a new transmembrane protein specifically expressed in adipose tissue. In obese subjects, short- or long-term calorie restriction diets were associated with a reduction in adiponutrin gene expression. Adiponut.rin mRNA level was previously shown to be negatively correlated with fasting glucose plasma levels and associated with insulin sensitivity of non-diabetic obese and non-obese subjects. The purpose of the present work was to get more insight into the regulation of adiponutrin gene expression by insulin and/or glucose using clamp studies and to examine its potential dysregulation in subjects with a deterioration of glucose homeostasis.
METHODS: Adiponutrin gene expression was quantified by reverse transcriptase-quantitative PCR in s.c. adipose tissue of healthy lean subjects after an euglycemic hyperinsulinemic clamp (EGHI), a hyperglycemic euinsulinemic clamp, and a hyperglycemic hyperinsulinemic (HGHI) clamp. Adiponutrin gene expression was also analyzed in patients with different levels of insulin resistance.
RESULTS: During EGHI, insulin infusion induced adiponutrin gene expression 8.4-fold (P = 0.008). Its expression was also induced by glucose infusion, although to a lesser extend (2.2-fold, P = 0.03). Infusion of both insulin and glucose (HGHI) had an additive effect on the adiponutrin expression (tenfold, P = 0.008). In a pathological context, adiponutrin gene was highly expressed in the adipose tissue of type-1 diabetic patients with chronic hyperglycemia compared with healthy subjects. Conversely, adiponutrin gene expression was significantly reduced in type-2 diabetics (P = 0.01), but remained moderately regulated in these patients after the EGHI clamp (2.5-fold increased).
CONCLUSION: These results suggest a strong relationship between adiponutrin expression, insulin sensitivity, and glucose metabolism in human adipose tissue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914601     DOI: 10.1530/eje.1.02229

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  26 in total

1.  Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease.

Authors:  Weiqin Chen; Benny Chang; Lan Li; Lawrence Chan
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells.

Authors:  Hae-Ki Min; Silvia Sookoian; Carlos J Pirola; Jianfeng Cheng; Faridoddin Mirshahi; Arun J Sanyal
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-24       Impact factor: 4.052

3.  Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells.

Authors:  Lei Hao; Kyoko Ito; Kuan-Hsun Huang; Sudathip Sae-tan; Joshua D Lambert; A Catharine Ross
Journal:  Metabolism       Date:  2014-06-21       Impact factor: 8.694

4.  The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.

Authors:  Yaron Rotman; Christopher Koh; Joseph M Zmuda; David E Kleiner; T Jake Liang
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro.

Authors:  S Pillai; S Duvvuru; P Bhatnagar; W Foster; M Farmen; S Shankar; C Harris; E Bastyr; B Hoogwerf; A Haupt
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

6.  Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity.

Authors:  M M J Guichelaar; S Gawrieh; M Olivier; K Viker; A Krishnan; S Sanderson; M Malinchoc; K D Watt; J M Swain; M Sarr; M R Charlton
Journal:  Obesity (Silver Spring)       Date:  2013-05-29       Impact factor: 5.002

7.  Low density lipoprotein delays clearance of triglyceride-rich lipoprotein by human subcutaneous adipose tissue.

Authors:  Simon Bissonnette; Huda Salem; Hanny Wassef; Nathalie Saint-Pierre; Annie Tardif; Alexis Baass; Robert Dufour; May Faraj
Journal:  J Lipid Res       Date:  2013-02-17       Impact factor: 5.922

8.  Body condition of late pregnant gilts affects the expression of selected adipokines and their receptors in mammary fat and backfat tissues.

Authors:  Cristiane R A Duarte; Chantal Farmer; Marie-France Palin
Journal:  J Anim Sci       Date:  2019-01-01       Impact factor: 3.159

9.  PNPLA3 mediates hepatocyte triacylglycerol remodeling.

Authors:  Hanna Ruhanen; Julia Perttilä; Maarit Hölttä-Vuori; You Zhou; Hannele Yki-Järvinen; Elina Ikonen; Reijo Käkelä; Vesa M Olkkonen
Journal:  J Lipid Res       Date:  2014-02-07       Impact factor: 5.922

10.  Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.

Authors:  Manju Kumari; Gabriele Schoiswohl; Chandramohan Chitraju; Margret Paar; Irina Cornaciu; Ashraf Y Rangrez; Nuttaporn Wongsiriroj; Harald M Nagy; Pavlina T Ivanova; Sarah A Scott; Oskar Knittelfelder; Gerald N Rechberger; Ruth Birner-Gruenberger; Sandra Eder; H Alex Brown; Guenter Haemmerle; Monika Oberer; Achim Lass; Erin E Kershaw; Robert Zimmermann; Rudolf Zechner
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.